Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin dose levels in R/R B-cell ALL
NCT03677596Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
A Phase 4 trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Pfizer. Started Jul 2019; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03677596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03677596.